Thyroid nodules are frequent clinical findings, but only a small proportion is malignant. Differential diagnosis and risk stratification for thyroid malignancy is, therefore, required to avoid unnecessary surgery. Could immunostaining of two protein markers ramp up a clinician's ability to distinguish lesions that require surgical intervention from those that do not?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo
Scientific Reports Open Access 01 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fadda, G. et al. Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur. J. Endocrinol. 165, 447–453 (2011).
British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer, 2nd edn [online]. (2007).
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).
Gharib, H. et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J. Endocrinol. Invest. 33 (Suppl. 5), 51–56 (2010).
Hegedus, L. Clinical practice. The thyroid nodule. N. Engl. J. Med. 351, 1764–1771 (2004).
Griffith, O. L., Chiu, C. G., Gown, A. M., Jones, S. J. & Wiseman, S. M. Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev. Anticancer Ther. 8, 1399–1413 (2008).
Cheung, C. C., Ezzat, S., Freeman, J. L., Rosen, I. B. & Asa, S. L. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod. Pathol. 14, 338–342 (2001).
Cheng, S., Serra, S., Mercado, M., Ezzat, S. & Asa, S. L. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin. Cancer Res. 17, 2385–2394 (2011).
Nikiforov, Y. E. et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 94, 2092–2098 (2009).
Ohori, N. P. et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol. 118, 17–23 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Boelaert, K., McCabe, C. Finding the malignant thyroid nodule in the haystack. Nat Rev Endocrinol 7, 563–564 (2011). https://doi.org/10.1038/nrendo.2011.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.152
This article is cited by
-
Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo
Scientific Reports (2021)
-
Noninvasive surface detection of papillary thyroid carcinoma by Fourier transform infrared spectroscopy
Chemical Research in Chinese Universities (2015)
